Amneal Pharmaceuticals enters the back half of August with an interesting split: the Street is turning more constructive just as short sellers are quietly adding pressure, creating one of the more nuanced setups in the generic pharma space right now.
The most significant development this week came from the analyst community. JP Morgan's Chris Schott reinstated coverage on August 26 with an Overweight rating and a $22 price target — a meaningful statement of confidence from a bellwether name. That follows UBS raising its target twice in six weeks, from $19 to $23 in mid-July and then to $25 in early August, while maintaining its Buy rating throughout. The Street's consensus now sits at Buy, with a mean target of $21 against a current price of $17.92 — roughly 17% implied return. Bulls point to Amneal's EPS momentum, which ranks in the 76th percentile on a 30-day basis and the 70th on a 90-day view, suggesting estimate revisions are running in the company's favor. The EV/EBITDA multiple has drifted lower by about half a turn over the past month to 9.8x, making the valuation setup modestly more attractive as the reinstatement lands.
Short interest, however, is moving in a different direction. Positions grew roughly 17% in a single session on August 25, pushing short interest to around 3% of the free float — a 20% increase over the past month. That absolute level remains low, and borrowing is cheap at under 0.5%, so there is no obvious squeeze dynamic here. What makes it notable is the direction: shorts have been steadily rebuilding after a quieter stretch in July. Availability remains extremely loose at nearly 7,800% of short interest, meaning there are many multiples more shares available to borrow than are currently out on loan, and the lending pool shows no signs of tightening. The cost to borrow has risen about 30% week-on-week, but in absolute terms it is still well under 0.5% — well within "easy borrow" territory for generics of this size.
Options positioning has shifted sharply toward bullish in the past two sessions and represents the clearest divergence from the short-interest trend. The put/call ratio dropped to 0.41 on August 25, nearly 1.7 standard deviations below its 20-day average of 0.57. That is a meaningfully call-heavy skew. Just a week earlier the PCR was running above 0.68, suggesting that something changed in trader sentiment around the time of the JP Morgan reinstatement. Call buyers are expressing more confidence than the put/call ratio has seen in months.
The insider picture adds a cautionary note. Five insiders sold shares in August, led by Chief Legal Officer Jason Daly (roughly $3.8 million across two transactions on August 11-12) and director J. Kevin Buchi ($2.9 million on August 11). The HR Director also sold $2.6 million worth of stock at similar prices. Net insider activity over the past 90 days is technically positive in share terms, but that reflects stock awards rather than open-market purchases — the recent cash-out pattern from C-suite and boardroom names is hard to ignore against a backdrop of analyst upgrades. Closely held stock remains significant: the Patel family collectively holds well over 30% of shares, with Tushar Patel adding over 12 million shares as recently as August 10.
Recent earnings reactions have been consistently soft. The most recent print on August 7 saw the stock fall just over 1% on the day before recovering. The prior quarter's release on July 30 was more damaging, with a 4% one-day decline extending to a 5.4% five-day loss. The next event is not until October 30, leaving the remainder of August and September as a period where the JP Morgan reinstatement thesis — and the divergence between call buyers and short-side rebuilding — will need to be tested against incoming data rather than a near-term catalyst. The key question for watchers is whether the analyst re-rating draws incremental institutional buyers or whether the insider selling pattern reflects a more cautious read on the path to the October print.
See the live data behind this article on ORTEX.
Open AMRX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
